COVID-19 in Patients with Primary Biliary Cholangitis

The aim of the study. To analyze the course of COVID-19 infection in patients with primary biliary cholangitis (PBC).

Materials and methods. In a single-center retrospective study, survey and analysis of medical records of 144 patients with PBC was carried out.

Results. All patients (n = 144) received basic therapy with ursodeoxycholic acid (UDCA), 5 of them received fibrates as well. Response to therapy (EASL criteria) was obtained in 30 people. Between March 2020 and March 2021, 50 patients (34.7 %) suffered COVID-19, with mean age of 58.8 ± 10.7 years, 16 of which were diagnosed with liver cirrhosis. Mild COVID-19 was observed in 34 (68 %) people, moderate course — in 14 (28 %), severe — in 2 (4 %), cases of extremely severe course were not recorded. 12 patients were hospitalized, 8 of which received oxygen therapy due to a decrease in SpO2 < 94 %, there was no need for the use of other methods of oxygen therapy in any case. The duration of hospitalization was 11.4 ± 5.7 days. There was a higher initial activity of serum alkaline phosphatase (1.8 ± 1.0 versus 1.7 ± 1.4 times of the upper limit of normal, M ± SD, p = 0.04) in patients with COVID-19 infection and lack of UDCA therapy effectiveness was more prominent (40 % vs. 19.1 % of cases, p = 0.04) compared with patients who did not have COVID-19. There were no significant differences in characteristics of the course of PBC (stage, response to therapy) and age in correlation with severity of the course of COVID-19. Among hospitalized patients and those in need of oxygen support, large proportion were older patients (58.3 % and 62.5 %, respectively) and patients with concomitant diseases (62.5 % and 75 %, respectively). Patients who hadn`t previously responded to UDCA therapy were more likely to require oxygen support compared to patients responding to basic therapy (p < 0.01).

Conclusion. PBC is not a risk factor for severe COVID-19. A protective effect of UDCA in SARS-CoV-2 infection is possible, which requires further investigation.

1. Nardo A.D., Schneeweiss-Gleixner M., Bakail M., Dixon E.D., Lax S.F., Trauner M. Pathophysiological mechanisms of liver injury in COVID-19. Liver Int. 2021;41:20–32. DOI: 10.1111/liv.14730

2. Kovalic A.J., Satapathy S.K., Thuluvath P.J. Prevalence of chronic liver disease in patients with COVID-19 and their clinical outcomes: a systematic review and meta-analysis. Hepatol Int. 2020;14:612–20. DOI: 10.1007/s12072-020-10078-2

3. Oyelade T., Alqahtani J., Canciani G. Prognosis of COVID-19 in Patients with Liver and Kidney Diseases: An Early Systematic Review and Meta-Analysis. Trop Med Infect Dis. 2020;5:80. DOI: 10.3390/tropicalmed5020080

4. Del Zompo F., De Siena M., Ianiro G., Gasbarrini A., Pompili M., Ponziani F.R. Prevalence of liver injury and correlation with clinical outcomes in patients with COVID-19: systematic review with meta-analysis. Eur Rev Med Pharmacol Sci. 2020;24:13072–88. DOI: 10.26355/eurrev_202012_24215

5. Marjot T., Moon A.M., Cook J.A., Abd-Elsalam S., Aloman C., Armstrong M.J., et al. Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study. J Hepatol. 2021;74(3):567–77. DOI: 10.1016/j.jhep.2020.09.024

6. Marjot T., Buescher G., Sebode M., Barnes E., Barritt A.S. 4th, Armstrong M.J., et al. SARS-CoV-2 infection in patients with autoimmune hepatitis. J Hepatol. 2021;74(6):1335–43. DOI: 10.1016/j.jhep.2021.01.021

7. Zecher B.F., Buescher G., Willemse J., Walmsley M., Taylor A., Leburgue A., et al. Prevalence of COVID-19 in patients with autoimmune liver disease in Europe: a patient-oriented online survey. United European Gastroenterol J. 2021;9(7):797–808. DOI: 10.1002/ueg2.12100

8. EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. J Hepatol. 2017;67(1):145–72. DOI: 10.1016/j.jhep.2017.03.022

9. Johns Hopkins University & Medicine (2020) “COVID-19 Dashboard” https://coronavirus.jhu.edu/map.html Accessed 16/02/2022

10. Romero Starke K., Reissig D., Petereit-Haack G., Schmauder S., Nienhaus A., Seidler A. The isolated effect of age on the risk of COVID-19 severe outcomes: a systematic review with meta-analysis BMJ Global Health 2021;6:e006434.

11. Cummings M.J., Baldwin M.R., Abrams D., Jacobson S.D., Meyer B.J., Balough E.M., et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. Lancet 2020;395:1763–70. DOI: 10.1016/S0140-6736(20)31189-2

12. Parra-Bracamonte G.M., Lopez-Villalobos N., Parra-Bracamonte F.E. Clinical characteristics and risk factors for mortality of patients with COVID-19 in a large data set from Mexico. Ann Epidemiol 2020;52:93–8. DOI: 10.1016/j.annepidem.2020.08.005

13. Rodal Canales F.J., Perez-Campos Mayoral L., Hernandez-Huerta M.T., Sanchez Navarro L.M., Matias-Cervantes C.A., Martinez Cruz M., et al. Interaction of Spike protein and lipid membrane of SARS-CoV-2 with Ursodeoxycholic acid, an in-silico analysis. Sci Rep 2021 Nov 15;11(1):22288. DOI: 10.1038/s41598-021-01705-5

14. Ko W.K., Lee S.H., Kim S.J., Jo M.J., Kumar H., Han I.B., et al. Anti-inflammatory effects of ursodeoxycholic acid by lipopolysaccharide-stimulated inflammatory responses in RAW 264.7 macrophages. PLoS One. 2017;12(6):e0180673. DOI: 10.1371/journal.pone.0180673

15. Abdulrab S., Al-Maweri S., Halboub E. Ursodeoxycholic acid as a candidate therapeutic to alleviate and/or prevent COVID-19-associated cytokine storm. Med Hypotheses. 2020;143:109897. DOI: 10.1016/j.mehy.2020.109897